Related Experiment Video
Updated: Jul 31, 2025
Generation of Human Neurons and Oligodendrocytes from Pluripotent Stem Cells for Modeling Neuron-Oligodendrocyte Interactions
Published on: November 9, 2020
Alpha-asaronol promoted oligodendrocyte precursor cell differentiation and improved myelination as an activator PPARγ
Zhaowei Feng1, Zixuan Gao2, Renyu Kong2
1Department of Neurology, Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu Province, China; Department of Cell Biology and Neurobiology, Xuzhou Key Laboratory of Neurobiology, Xuzhou Medical University, Xuzhou, Jiangsu Province, China.
Insights
Alpha-asaronol promotes oligodendrocyte differentiation and myelin repair in preterm white matter injury by activating PPARγ. This compound may offer a therapeutic strategy for myelination failure in premature infants.
Area of Science:
- Neuroscience
- Developmental Biology
- Pharmacology
Background:
- Preterm white matter injury (PWMI) impairs oligodendrocyte differentiation and myelination in premature infants.
- Peroxisome proliferator-activated receptor γ (PPARγ) activation shows potential in promoting oligodendrocyte differentiation.
- The precise mechanism of alpha-asaronol's effect on myelination disorders was previously unclear.
Purpose of the Study:
- To elucidate the mechanism by which alpha-asaronol promotes oligodendrocyte differentiation and myelin repair in a neonatal PWMI rat model.
- To investigate the role of PPARγ activation in alpha-asaronol's therapeutic effects.
- To assess the potential of alpha-asaronol as a treatment for myelination failure.
Main Methods:
- Utilized a neonatal rat model of PWMI.
- Administered alpha-asaronol and assessed cognitive deficits, myelin damage, and oligodendrocyte differentiation.
- Performed co-immunoprecipitation to analyze protein interactions (PPARγ and PGC-1α).
- Measured gene expression of PTEN, Cnp1, Klk6, and Clk1.
- Used GW9662, a PPARγ antagonist, to block alpha-asaronol's effects.
- Tested alpha-asaronol's efficacy on oligodendrocyte precursor cells under oxygen-glucose deprivation.
Main Results:
- Alpha-asaronol attenuated cognitive deficits and repaired myelin damage in PWMI rats.
- Alpha-asaronol stimulated oligodendrocyte differentiation by inducing PPARγ and PGC-1α binding, activating PPARγ.
- This activation modulated the expression of key differentiation-associated genes (PTEN, Cnp1, Klk6, Clk1).
- The beneficial effects of alpha-asaronol were reversed by the PPARγ antagonist GW9662.
- Alpha-asaronol promoted oligodendrocyte precursor cell differentiation in vitro.
Conclusions:
- Alpha-asaronol promotes oligodendrocyte differentiation and myelination in neonatal PWMI by activating PPARγ signaling.
- The mechanism involves modulating specific gene expression related to oligodendrocyte differentiation.
- Alpha-asaronol demonstrates potential as a therapeutic agent for myelination failure in preterm infants.
Abstract:
Preterm white matter injury (PWMI), characterized by oligodendrocyte precursor cell (OPC) differentiation disorder and dysmyelination, is a prevalent demyelinating disease of the central nervous system in premature infants, necessitating the development of mitigating strategies. Convincing evidence suggests that peroxisome proliferator-activated receptor γ (PPARγ) activation is a stimulative factor against the hindered process of oligodendrocyte (OL) differentiation. However, much remains unknown about its promotive mechanism. Our previous study indicated that alpha-asaronol (α-asaronol) could alleviate myelination disorder in a neonatal PWMI rat model, but the mechanism remained unclear. In this study, we demonstrated that α-asaronol attenuated cognitive deficits, repaired myelin damage, and stimulated OL differentiation in the corpus callosum of PWMI rats. Co-immunoprecipitation analysis confirmed that α-asaronol induced the binding of PPARγ with its coactivator peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α), which in turn activated oligodendroglial PPARγ. This activation subsequently upregulated the expression of phosphatase and tensin homolog (PTEN) and pro-differentiation-associated genes of Cnp1 and Klk6 and downregulated the expression of Clk1. However, the benefits of α-asaronol were blocked by GW9662, an antagonist of PPARγ. Moreover, α-asaronol also promoted OPC differentiation under oxygen-glucose deprivation conditions. In conclusion, α-asaronol can promote OL differentiation and myelination and alleviate cognitive deficits in neonatal PWMI rats by activating PPARγ and modulating OL differentiation-associated gene expression. This study suggests that α-asaronol may be a potential therapeutic drug for myelination failure in PWMI.
